# Hornet Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hornet-therapeutics

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.hornet-tx.com
- Latest round: Seed (May 28, 2024)
- Investors on record: 1

## About

Based in London, UK, and founded in 2019 by 4BIO Capital and co-founder Christoph Hess, Hornet Therapeutics Ltd operates as a healthcare company that helps in researching and developing treatments for the Epstein-Barr virus and EBV. In May 2024, Hornet Therapeutics Ltd raised seed funding from 4BIO Capital Partners.

Hornet Therapeutics Ltd developed product known as HTX-201, which is an IDO-1 inhibitor in-licensed from Kyowa Kirin that enter clinical trials as a potential treatment for preventing EBV-related diseases, including post-transplant lymphoproliferative disease (PTLD). The company by inhibiting IDO-1, HTX-201 focuses to disrupt the EBV infection process. In addition, the firm provides treatments to address EBV-driven pathologies and epstein-barr virus (EBV) driven disease. 

The company plans to use the funding from May 2024 to emerge from stealth with a strategic partnership with Kyowa Kirin and seed financing by 4BIO Capital.

## Funding rounds

- Seed, May 28, 2024 — 4BIO Capital Partners

## Investors

- 4BIO Capital Partners (https://capitalatlas.ai/funds/4bio-capital-partners) — Seed